Effectiveness of Extracorporeal Shockwave Therapy Combined With Platelet-rich Plasma in the Treatment of Chronic Insertional Achilles Tendinopathy

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06384859

Enrollment

Registered

2024-04-25

Start date

2024-05-01

Completion date

2027-05-01

Last updated

2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insertional Achilles Tendinopathy

Keywords

chronic insertional Achilles tendinopathy, extracorporeal shockwave therapy, platelet rich plasma

Brief summary

The goal of this clinical trial is to learn about the effectiveness of extracorporeal shockwave(ESWT) combined with platelet-rich plasma(PRP) to treat chronic insertional tendinopathy. The main questions it aims to answer are: Does ESWT combined with PRP treatment reduce the symptom and improve functional score after treatment? What medical complication do participants have when receive the treatment? Researchers will compare ESWT combined with PRP to ESWT treatment alone to see if ESWT combined with PRP works to treat chronic insertional tendinopathy. Participants will: * Receive ESWT once a week for 4 weeks then receive PRP injection at a week later or ESWT once a week for 4 weeks * Visit the clinic at 6 weeks, 3 months, 6 months and 1 year after treatment for checkups and record functional score

Interventions

DEVICEESWT

Receive ESWT once a week for 4 weeks

BIOLOGICALPRP

Receive PRP injection at week 5

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with insertional Achilles tendinopathy * Had symptom more than 6 months * Failed other standard conservative treatment (rest, medication, activity modification, stretching exercise, and heel lift orthosis)

Exclusion criteria

* Receive corticosteroid injection at the Achilles insertion * History of infection around ankle and heel * Has neurological deficit * Has a contraindication for ESWT(hemophilia, coagulopathy or foot and ankle malignancy)

Design outcomes

Primary

Measure	Time frame	Description
VAS	6 week, 3 months, 6 months and 1 year after treatment	Visual Analogue Scale

Secondary

Measure	Time frame	Description
VAS-FA	6 week, 3 months, 6 months and 1 year after treatment	Visual analogue scale foot and ankle
FFI	6 week, 3 months, 6 months and 1 year after treatment	Foot functional index
FAAM	6 week, 3 months, 6 months and 1 year after treatment	Foot and Ankle Ability Measure

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026